.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,258,830

« Back to Dashboard

Claims for Patent: 6,258,830

Title: Stable gel formulation for topical treatment of skin conditions
Abstract:The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from-the gel to the skin condition.
Inventor(s): Charu; Prakash M. (Fullerton, CA)
Assignee: Allergan Sales, Inc. (Irvine, CA)
Application Number:09/260,217
Patent Claims: 1. A stable gel formulation for topical treatment of both acne and psoriasis comprising:

an effective amount of a synthetic retinoid comprising Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate;

Polysorbate 40 present in an amount greater than 0% and up to about 0.4 wt %;

Poloxamer 407 present in an amount greater than 0% and up to about 0.4 wt %; and

hexylene glycol present in the amount of about 2 wt %, wherein said Polysorbate 40, hexylene glycol, and optionally Poloxamer 407 are present in amounts to control release of the synthetic retinoid from the gel to the skin of a patient with acne or psoriasis.

2. A stable gel formulation for topical treatment of both acne and psoriasis comprising:

an effective amount of a synthetic retinoid comprising Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl]nicotinate;

Polysorbate 40 present in an amount greater than 0% and up to about 0.4 wt %;

Poloxamer 407 present in an amount greater than 0%; and

hexylene glycol present in an amount of about 2 wt %, wherein said Polysorbate 40, hexylene glycol, and optionally Poloxamer 407 are present in amounts to control solubility of the synthetic retinoid from the gel.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc